arteriovenous malformation (AVM) 269
arteriovenous fistulae (AVF) 269
arterial spasm 433
arterial rupture, intravascular ultrasound 81, 778
Aspirex device 496
ASPIRE study 427, 472
aspiration thrombectomy 259
ascorbic acid, contrast-induced acute kidney injury 778
ARTS 1 trial 144
ARTE study 514
arterial conduits, PCI in 203
arrhythmogenic RV cardiomyopathy (ARVC) 130
arrhythmia, atrial septal defect closure 538
ARMYDA‐5 PRELOAD trial 400
ARMYDA‐2 trial 399
ARMOUR trial 657
arm claudication, Takayasu’s arteritis 748
arterial conduits, PCI in 203
arterial rupture, intravascular ultrasound 81, 778
Aspirin 381, 398–399, 474–476, 475, 754–755
atropine 662
atrial tachyarrhythmias 590
atrial tachyarrhythmias 590
atrial tachyarrhythmias 590
atrial tachyarrhythmias 590
atrial tachyarrhythmias 590
nitrateglycerin 432
carotid artery stenosis 666
no-reflow phenomenon 261
radial artery stenosis 30, 433
nitrateglycerine (glycerine trinitrate) 432
nitropusside, no-reflow phenomenon 261–262, 433
NOBORI I trial 354–357, 355
NOBORI 2 study 354, 355
NOBORI CORE study 354, 355
NOBORI PK study 355
Nobori stent 354–357, 370, 372
case study 101, 101–103, 102, 103
coronary angiography vs. 34
clinical evidence 354, 355
drug-eluting stent vs. 354–357
ongoing studies 357
pharmacokinetic studies 354
preclinical studies 354
randomized studies 354–357, 356
registries 354
sirolimus-eluting stent vs. 354
non-compaction cardiomyopathy 130
non-inferiority designs, clinical trial 299, 300
non-ischemic cardiomyopathies 130
non-occlusive mesenteric ischemia (NOMI) 699, 699
non-steroidal anti-inflammatory drugs (NSAIDs), discontinuation prior to PCI 433–434, 434
non-ST segment elevation acute coronary syndromes (NSTEMI) 148–154
adjunctive pharmacologic treatment 150–153, 151
coronary revascularization 149–150
direct thrombin inhibitors 410, 411–412, 416
bivalirudin 153, 410, 411–412, 416, 427, 473
dual antiplatelet therapy 438
factor Xa inhibitors 413
glycoprotein IIb/IIIa inhibitors 411–412, 416, 427, 473
imaging 72
incidence 259
prevention 259–261
prognosis 262–263
treatment 261, 261–262
vasodilators 432–433
norepinephrine see noradrenaline
notification radiation dose level 286
NSTEMI see non-ST segment elevation acute coronary syndromes (NSTEMI)
nuclear factor kB (NFkB), atherosclerosis 7
null hypothesis 299
number needed to treat (NNT) 297
Nurse's Health Study 461
OASIS-5 trial 427, 437, 472
OASIS-6 trial 427, 472
odds ratio 297
OMEGA trial 327
omeprazole, clopidogrel and 448
ON-TIMI-2 trial 417
open popliteal aneurysm repair (OPAR) 735
opioids, PCI peri-procedural sedation 433
optical coherence tomography (OCT) 91–98
artifacts 92–93, 93
atherosclerosis 5
bifurcation lesions 183
bioresorbable vascular scaffolds 335–336, 337, 339
calibration 92
in-stent restenosis 220
in-stent re-crossing guidance 97
intramural hematoma 250, 251
IVUS vs. 91, 96
multiple reflections 93, 93
multivessel coronary artery disease 186
non-uniform rotational distortion 92
percutaneous coronary intervention 95–96, 96
plaque characteristics 5, 6, 93–94, 94, 95
plaque rupture 5
post-processing 92
principles 91
residual blood 92, 93
small vessel disease 206
stenotic edge dissections 249–250
stenotic re-crossing guidance 97
stenosis 235
strut coverage analysis 97–98
system 91–93, 92
thrombus 234, 234–235
tissue protrusion 97
unprotected left main coronary artery disease 170
vulnerable plaque imaging 93
Z-score 92
optical frequency domain imaging 91, 92
OPTUS-TIMI 16 trial 444
oral anticoagulants (OCA) 444–446
antiplaquette therapy and 444–445
dual antiplatelet therapy and 446, 448
long-term 443–452
see also anticoagulation
orbital atherectomy 225, 229–230, 230, 730
critical limb ischemia 745
endothelial 442, 444
Orsiro Clinical Program 363–364
ORSIRO stent 361–362, 372
clinical evidence 362, 363–364, 365
STEMI 362
orthogonal-platypteren syndrome 531
ostial lesions, multislice computed tomography 110–112, 115
Ostial Pro stent positioning system 710
otamixaban 385
Ovation device 694, 694
OVER trial 695
oxidative stress markers 11
oxidized LDL (ox-LDL) 7
P2Y12 ADP receptor antagonists 381–382, 382, 476–477
duration of treatment 437
ischemic and bleeding complications 382, 392–393
monitoring 477
non-ST segment elevation acute coronary syndromes 152
reversal 477
see also individual drugs
P2Y12 receptor 379, 453, 454
pacemakers, cardiac magnetic resonance 128
PACIFIER trial 729
paclitaxel 369
drug-eluting balloons 245
resistance 218
paclitaxel-eluting stents (PES) 301–312
acute myocardial infarction 304
bare metal stents vs. 302, 302–303, 308, 308
BioFreedom stent vs. 353
FDS approval 301
meta-analyses 308–310
metallic alloys 368
multivessel disease 304–308
polymer coating 369
randomized trials 308–310
registries 308–310
sirolimus-eluting stent vs. 308–309, 310
stenosis 302, 308
Xience stents vs. 319
Paget-Schroetter syndrome 749, 751, 765–766
Palmaz-Schatz stent 258
papaverine, hyperemia induction 61
papillary muscle shortening 597
papillary muscle sliding plasty 597
PAR-1 antagonists (inhibitors) 383
Paradise system 502, 504
paravalvular leak (PVL) 561, 633, 633
paravalvular leak closure 633–634
paravalvular regurgitation 541
clinical features 540
diagnostic evaluations 540–541
imaging 540–541
laboratory tests 540
localization 541
mitral 541
pathophysiology 540
PARIS registry 405
PARIS trial 438
PARTNER II S3 trial 575
PARTNER trial 512, 548
balloon aortic valvuloplasty 547
PASSION trial 304
patent foramen ovale (PFO) 530
cryptogenic stroke and 530–531
types 530
patent foramen ovale closure 530–539
adverse events 538–539
aftercare 539
antithrombotic management 531
closure procedure 536
completing 538
contraindications 532–535
cryptogenic stroke 508, 511, 530–531, 643
future directions 539
imaging 535, 535–536
occluder devices 532, 533–534, 536
delivery 537–538
embolization 538
selection 536
premedication 532–535
secondary stroke/TIA prevention 531
technique 532–536
transseptal puncture 536, 588
patent hemostasis, transradial access (TRA) 32
pathophysiological trial 592
PCI see percutaneous coronary intervention (PCI)
PACS-CURE trial 438
PCS9 inhibitors 461
PEITHO study 493

penile arterial revascularization 715–718
penile arterial inflow (PAI) disease 713
penile arterial inflow (PAI), erectile dysfunction 715,
penile arterial inflow (PAI), erectile dysfunction 715–718
penile arterial revascularization 715–718
endovascular approach 717–718, 718
outcomes 717
patient selection/ Work up 718
surgical approach 715–716
penis
anatomy 713–714
arterial variants 714
blood supply 713–714, 714
PENTALYSE study 472
pentasaccharides 472–473
PENTUA study 472
Penumbra System 645
PEPCAD China JISR trial 246
PEPCAD II trial 245
Perclose ProGuide device 20–21
PEPCAD II trial 245
Perclose ProGuide device 20–21, 21, 23
transcatheter aortic valve replacement 551, 562
vascular complications 22
percutaneous coronary intervention (PCI)
acute postoperative graft failure 202
adverse outcomes 389
after coronary artery bypass graft failure 201–202
antiarrhythmic drugs 432–435
antiplatelet agents 421–423
parenteral 415–420
arterial conduits 203
bleeding complications
definitions 389, 391
mortality risk 389
outcomes 389–391
pharmacologic reduction strategies 391–394
risk assessment 391
degenerated saphenous vein grafts 202–203
drugs to discontinued prior to 433–434
inotropes during 434
ischemic complications
definitions 389, 390
outcomes 389–391
pharmacologic reduction strategies 391–394
risk assessment 391
multivessel coronary artery disease 187, 188
non-ST segment elevation acute coronary syndromes 148–154
optical coherence tomography 95–98, 96
for guidance 96
parenteral agents, stable patients 421–431
peri-procedural sedation 433, 433
prior to transcatheter aortic valve replacement 561
rescue, in acute myocardial infarction 158–159
stable angina 138–143
triple vessel 188
unfractionated heparin 423–426
unprotected left main coronary artery disease 168–174, 169
vasoactive drugs 432–435
vasopressors during 434
vein grafts 201–204
see also specific clinical indications
warfarin
atrial fibrillation 439
dosing 466
following PCI 444–445
left atrial appendage exclusion 528
pharmacogenetics 466–467
triple antithrombotic therapy 448
Watchman device 525–526, 526
anticoagulation 528
deployment 527
positioning 527
release criteria 528
water hammer effect 760
Wavecrest left atrial appendage Occlusion system 526, 526
WEB flow diverter 675
Whisper trial 341
white thrombi 94
whole exome/whole genome sequencing (WES/WGS), CAD 460–461
wire support 47–48
see also guidewire(s)
WOEST trial 440, 446
woodpecking sign 611
Woven Endobridge 675
wrist-brachial index (WBI) 749, 750
xemilofiban 402, 444
Xience Prime stent 317
Xience stent(s)
ABSORB bioresorbable vascular scaffold vs. 338
bare metal stent vs. 322
clinical trials 319–323, 320–321
Nobori stent vs. 356
ORSIRO stent vs. 362
paclitaxel-eluting stents vs. 319
polymer 317–318, 318
sirolimus-eluting stents vs. 322
see also everolimus-eluting stents (EES)
Xience V stent 317, 318, 322, 371
XIENCE V USE prospective multicenter registry 323
Xpedition everolimus-eluting stent 317
X-rays 282
X-Sizer 238
XTENT Custom NX stent 357
YELLOW trial 99
Zenith devices 689, 694, 694
ZEN trial 717
Zilver PTX trial 734
zotarolimus-eluting stent (ZES)
BioMatrix stent vs. 351
dual antiplatelet therapy and 438
durable polymers 369–370
everolimus-eluting stents vs. 322, 329
Orsiro stent vs. 362
unprotected left main coronary artery disease 169
Xience stents vs. 322